SOPHiA GENETICS (NASDAQ:SOPH) Stock Price Down 5.5% – Here’s What Happened

SOPHiA GENETICS SA (NASDAQ:SOPH) shares traded down 5.5% during trading on Tuesday. The stock traded as low as $7.80 and last traded at $7.75. Approximately 414,599 shares traded hands during trading, an increase of 36% from the average daily volume of 304,445 shares. The stock had previously closed at $8.20.

Analysts Set New Price Targets

SOPH has been the topic of a number of research analyst reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of SOPHiA GENETICS in a research report on Friday, July 17th. BTIG Research raised their price target on SOPHiA GENETICS from $8.00 to $9.00 and gave the company a “buy” rating in a report on Wednesday, August 5th. Zacks Research raised SOPHiA GENETICS to a “hold” rating in a report on Tuesday, July 21st. Finally, HC Wainwright upped their price target on shares of SOPHiA GENETICS from $12.00 to $14.00 and gave the company a “buy” rating in a research note on Wednesday, August 5th. Three research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $10.00.

SOPHiA GENETICS Price Performance

The firm has a market capitalization of $631.69 million, a P/E ratio of -6.55 and a beta of 0.95. The company has a current ratio of 2.69, a quick ratio of 2.55 and a debt-to-equity ratio of 0.58. The firm has a 50 day moving average price of $7.78 and a 200-day moving average price of $6.10.

SOPHiA GENETICS (NASDAQ:SOPH) last released its quarterly earnings results on Wednesday, August 5th. The company reported ($0.26) earnings per share for the quarter, missing the consensus estimate of ($0.21) by ($0.05). The company had revenue of $23.31 million for the quarter, compared to analysts’ expectations of $21.72 million. SOPHiA GENETICS had a negative net margin of 93.86% and a negative return on equity of 132.47%. On average, analysts expect that SOPHiA GENETICS SA will post -0.77 earnings per share for the current year.

Insider Transactions at SOPHiA GENETICS

In other SOPHiA GENETICS news, insider Zhenyu Xu sold 17,000 shares of the business’s stock in a transaction that occurred on Friday, August 7th. The stock was sold at an average price of $7.29, for a total transaction of $123,930.00. Following the completion of the transaction, the insider owned 590,887 shares in the company, valued at $4,307,566.23. The trade was a 2.80% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Chairman Jurgi Camblong sold 24,381 shares of the company’s stock in a transaction that occurred on Monday, July 20th. The shares were sold at an average price of $6.29, for a total value of $153,356.49. Following the transaction, the chairman directly owned 3,512,822 shares in the company, valued at approximately $22,095,650.38. This represents a 0.69% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 217,745 shares of company stock valued at $1,560,269. 4.88% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On SOPHiA GENETICS

A number of institutional investors and hedge funds have recently modified their holdings of SOPH. Maven Securities LTD bought a new position in SOPHiA GENETICS in the 2nd quarter valued at $866,000. AXQ Capital LP purchased a new position in SOPHiA GENETICS in the 2nd quarter worth about $119,000. AWM Investment Company Inc. bought a new stake in SOPHiA GENETICS during the 2nd quarter valued at about $9,809,000. Hennion & Walsh Asset Management Inc. purchased a new stake in SOPHiA GENETICS in the 2nd quarter valued at about $567,000. Finally, Royal Bank of Canada grew its stake in SOPHiA GENETICS by 3,130.2% in the 1st quarter. Royal Bank of Canada now owns 19,381 shares of the company’s stock worth $96,000 after acquiring an additional 18,781 shares in the last quarter. 31.59% of the stock is owned by institutional investors.

SOPHiA GENETICS Company Profile

SOPHiA GENETICS is a healthcare technology company that develops cloud-based data analytics solutions for the life sciences and healthcare industries. Its platform is designed to help organizations analyze and interpret complex genomic and multimodal data to support more informed clinical and research decisions.

The company’s principal offering, the SOPHiA DDM platform, combines data management, analytics and artificial intelligence capabilities. It supports applications including cancer genomics, hereditary disease analysis, reproductive health and other areas of precision medicine.